Qvar Redihaler (Beclomethasone Dipropionate) Patent Expiration, LOE Window & CMS Spending

Qvar Redihaler (Beclomethasone Dipropionate) by Norton Waterford: FDA Orange Book LOE 2041-08-19, 2 AB generics, $146.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNorton Waterford
FDA Application & PathwayN207921 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-08-19
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$146.3M
2024 Medicare Part D Spend$72.5M
2024 Medicaid Spend$73.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel